Dec 15, 2021, 12:30 AM
AcuraStem (, a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.
Dec 6, 2021, 5:01 PM
AcuraStem will present posters at the 32nd International Symposium on ALS/MND.